Adicet Bio, Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 6 compared factors.
Size & Scale
| ACET | LLY | |
|---|---|---|
| Market Cap | $59.45 million | $1.05 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | $-98,974,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ACET | LLY | |
|---|---|---|
| P/E Ratio | — | 39.77 |
| Price / Book | 0.49 | 31.14 |
| Price / Sales | — | 13.24 |
ACET leads on 1 of 1 valuation factors.
Profitability
| ACET | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | -82.38% | 78.84% |
LLY leads on 1 of 1 profitability factors.
Dividend
| ACET | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
ACET and LLY split the dividend factors evenly.
Risk & Sentiment
| ACET | LLY | |
|---|---|---|
| Short Interest | 13.28% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: ACET overview, ACET financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
